Table SI.Primers used to amplify the indicated genes.

| Gene | Reverse transcription-quantitative PCR primers |  |
| :---: | :---: | :---: |
|  | Forward Sequence (5' $\left.5^{\prime}-3^{\prime}\right)$ | Reverse sequence (5 $\left.5^{\prime}-3^{\prime}\right)$ |
| TPR | AACGCCAGCGTGAGGAATATG | ATTACGTGGTTACCCCTTGCT |
| GAPDH | ACAGTCAGCCGCATCTTCTT | GACAAGCTTCCCGTTCTCAG |

Table SII. Antibodies used in western blotting

| Antibody target | Vendor | Cat.no. |
| :--- | :--- | :---: |
| TPR | Abcam | ab170940 |
| phospho-AKT (S473) | CST | 4060 |
| AKT | CST | 9272 |
| GAPDH | CST | 2118 |
| Goat anti-rabbit IgG | Bioworld Technology, Inc. | bs13278 |

Table SIII.Association between the expression of TPR and the clinicopathological characteristics of patients

| Characteristics | Low expression of TPR | High expression of TPR | P -value |
| :---: | :---: | :---: | :---: |
| n | 187 | 187 |  |
| T stage, n (\%) |  |  | 0.813 |
| T1 | 92 (24.8\%) | 91 (24.5\%) |  |
| T2 | 49 (13.2\%) | 46 (12.4\%) |  |
| T3 | 36 (9.7\%) | 44 (11.9\%) |  |
| T4 | 7 (1.9\%) | 6 (1.6\%) |  |
| N stage, n (\%) |  |  | 0.624 |
| N0 | 121 (46.9\%) | 133 (51.6\%) |  |
| N1 | 1 (0.4\%) | 3 (1.2\%) |  |
| M stage, n (\%) |  |  | 0.365 |
| M0 | 131 (48.2\%) | 137 (50.4\%) |  |
| M1 | 3 (1.1\%) | 1 (0.4\%) |  |
| Pathologic stage, n (\%) |  |  | 0.294 |
| Stage I | 87 (24.9\%) | 86 (24.6\%) |  |
| Stage II | 47 (13.4\%) | 40 (11.4\%) |  |
| Stage III | 37 (10.6\%) | 48 (13.7\%) |  |
| Stage IV | 4 (1.1\%) | 1 (0.3\%) |  |
| Tumor status, n (\%) |  |  | 0.226 |
| Tumor free | 108 (30.4\%) | 94 (26.5\%) |  |
| With tumor | 71 (20\%) | 82 (23.1\%) |  |
| Sex, n (\%) |  |  | 0.269 |
| Female | 55 (14.7\%) | 66 (17.6\%) |  |
| Male | 132 (35.3\%) | 121 (32.4\%) |  |
| Race, n (\%) |  |  | 0.815 |
| Asian | 76 (21\%) | 84 (23.2\%) |  |
| Black or African American | 8 (2.2\%) | 9 (2.5\%) |  |
| White | 94 (26\%) | 91 (25.1\%) |  |
| Residual tumor, n (\%) |  |  | 0.086 |
| R0 | 168 (48.7\%) | 159 (46.1\%) |  |
| R1 | 5 (1.4\%) | 12 (3.5\%) |  |
| R2 | 1 (0.3\%) | 0 (0\%) |  |
| Histologic grade, n (\%) |  |  | 0.046 |


| G1 | $35(9.5 \%)$ | $20(5.4 \%)$ |
| :--- | :---: | :---: |
| G2 | $93(25.2 \%)$ | $85(23 \%)$ |
| G3 | $52(14.1 \%)$ | $72(19.5 \%)$ |
| G4 | $5(1.4 \%)$ | $7(1.9 \%)$ |

Adjacent hepatic tissue inflammation, n (\%)
None

Mild

| $67(28.3 \%)$ | $51(21.5 \%)$ |
| :---: | :---: |
| $48(20.3 \%)$ | $53(22.4 \%)$ |
| $12(5.1 \%)$ | $6(2.5 \%)$ |

Child-Pugh grade, n (\%)
A
B
C

Fibrosis ishak score, n (\%)
0
$1 / 2$
3/4
5/6
Vascular invasion, n (\%)
No
Yes
Age, median (IQR)
Height, median (IQR)
Weight, median (IQR)
BMI, median (IQR)
AFP ( $\mathrm{ng} / \mathrm{ml}$ ), median (IQR)
Albumin(g/dl), median (IQR)
Prothrombin time, median (IQR)
Categorical variables are expressed as frequencies and percentages. Continuous variables, including parametric and nonparametric variables, are indicated as the mean $\pm$ standard deviation (SD) and median with interquartile range, respectively. TPR, translocatedpromoter region.

